Gold & Gold Compounds

BreastfeedingPediatric
  • TRADE NAMES: Aureotan; Aurolate; Aurothio; Miocrin; Myochrysine (Merck); Myocrisin (Sanofi-Aventis); Ridaura (Prometheus); Shiosol; Solganal (Schering); Tauredon
  • INDICATIONS: Rheumatoid arthritis
  • SYNONYM: auranofin; aurothioglucose
  • CLASS: Disease-modifying antirheumatic drug (DMARD)
  • HALF-LIFE: 5 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

ACE inhibitors, Benazepril, Captopril, Cilazapril, Enalapril, Fosinopril, Lisinopril, Penicillamine, Phenytoin, Quinapril, Ramipril, Trandolapril

PREGNANCY CATEGORY: C

Contra-indicated in patients with a history of any of the following gold-induced disorders: anaphylactic reactions, necrotizing enterocolitis, pulmonary fibrosis, exfoliative dermatitis, bone marrow aplasia or other severe hematologic disorders.

Adverse reactions can occur months after therapy has been discontinued.

Our database has 99 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
GENITOURINARY
RENAL
HEMATOLOGIC
OCULAR
LOCAL
OTHER


Page last updated 02/27/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric